Navamedic ASA launches ForlaxGO® - an innovative on-the-go product for the treatment of constipation

OSLO, Norway, Oct. 20, 2022 /PRNewswire/ -- Navamedic ASA (OSE: NAVA) today announces the launch of ForlaxGO^® across pharmacies in Norway, Sweden, Finland and Denmark. ForlaxGO^® is a unique product that relieves the symptoms of occasional constipation in adults and children above 8 years of age. The launch is part of a long-term agreement with Ipsen Consumer HealthCare, a reputable French pharmaceutical company, whereby Navamedic is the exclusive partner in the Nordics.

"Following the long-term agreement with Ipsen and the subsequent launch of SmectaGO^® in February, we are pleased to announce the launch of ForlaxGO^®, the second product launch stemming from this agreement. With only 20 percent of those suffering from constipation and other gastro conditions seeking treatment, we believe we can improve people's lives by making products such as ForlaxGO^® accessible and increasing awareness of treatment options. ForlaxGO^® is already well established on the European continent, and we are confident that our local insight and market access will drive the development of this treatment category in the Nordics," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

ForlaxGO^® is an on-the-go, ready-to-drink suspension that relieves the symptoms of occasional constipation in adults and children above 8 years of age. The main component of the product is macrogol, which provides a sense of natural relief. ForlaxGO^® is presented as a ready-to-use solution in a single-dose sachet and can be bought at pharmacies without a prescription.

Constipation is defined as slow, hard or infrequent stools. The problem is widespread among older people and is three times as common among women as men. 20 percent of the population experience or live with constipation, and about 10 percent use laxatives.

"We continue to accelerate growth by launching new products such as ForlaxGO^®, underpinning our target of 20 percent annual organic growth and the mid-term ambition of building a NOK 1 billion company," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality products, delivered to hospitals and through pharmacies, meeting the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.